Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 25, 2010, Pages 11608-11613

  Melief, Erica J ^a   Miyatake, Mayumi ^a   Bruchas, Michael R ^a   Chavkin, Charles ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acute analgesic tolerance; Biased agonism; Collateral agonist; Desensitization

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BUPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; G PROTEIN COUPLED RECEPTOR; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; METHADONE; MITOGEN ACTIVATED PROTEIN KINASE 10; MORPHINE; MORPHINE 6 GLUCURONIDE; MU OPIATE RECEPTOR; OPIATE RECEPTOR; OXYCODONE; PERTUSSIS TOXIN; ANALGESIC AGENT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; NARCOTIC ANALGESIC AGENT; STRESS ACTIVATED PROTEIN KINASE;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; DRUG MECHANISM; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL MEMBRANE; CHEMISTRY; CYTOLOGY; METABOLISM; MOUSE MUTANT; SPINAL CORD;

MUS;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CELL MEMBRANE; ENZYME ACTIVATION; FENTANYL; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIGANDS; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MORPHINE; OXYCODONE; RECEPTORS, OPIOID; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 77954923289     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1000751107     Document Type: Article

References (40)

1. Berg KA, et al. (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: Evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
2. Drake MT, et al. (2008) beta-Arrestin-biased agonism at the beta2-adrenergic receptor. J Biol Chem 283:5669-5676.
3. Galandrin S, et al. (2008) Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol 74:162-172.
4. Urban JD, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
5. Kenakin T (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol Pharmacol 72:1393-1401.
6. Bruchas MR, et al. (2007) Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J Biol Chem 282:29803-29811.
7. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: Implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
8. Horan P, Taylor J, Yamamura HI, Porreca F (1992) Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther 260:1237-1243.
9. Reisine T (1995) Opiate receptors. Neuropharmacology 34:463-472.
10. Kovoor A, Celver JP, Wu A, Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54:704-711.
11. Zhang J, et al. (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95: 7157-7162.
12. Chu J, Zheng H, Loh HH, Law PY (2008) Morphine-induced mu-opioid receptor rapid desensitization is independent of receptor phosphorylation and beta-arrestins. Cell Signal 20:1616-1624.
13. Keith DE, et al. (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
14. Johnson EA, et al. (2006) Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70:676-685.
15. Terman GW, et al. (2004) G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 141:55-64.
16. Bennett BL, et al. (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686.
17. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517-532.
18. Lawrence AJ, Michalkiewicz A, Morley JS, MacKinnon K, Billington D (1992) Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions. Biochem Pharmacol 43:2335-2340.
19. Zaki PA, Keith DE, Jr, Brine GA, Carroll FI, Evans CJ (2000) Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292:1127-1134.
20. Minnis JG, et al. (2003) Ligand-induced mu opioid receptor endocytosis and recycling in enteric neurons. Neuroscience 119:33-42.
21. Beyer A, Koch T, Schröder H, Schulz S, Höllt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-560.
22. Celver J, Xu M, Jin W, Lowe J, Chavkin C (2004) Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol Pharmacol 65:528-537.
23. Arttamangkul S, et al. (2008) Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 74:972-979.
24. Hull LC, et al. (2010) The effect of PKC and GRK inhibition on tolerance induced by mu opioid agonists of different efficacy. J Pharmacol Exp Ther 332:1127-1135.
25. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M (2005) Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25:7847-7857.
26. Matthes HW, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383: 819-823.
27. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ (2003) Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278:18776-18784.
28. Bünemann M, Hosey MM (1999) G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 517:5-23.
29. Lowe JD, Celver JP, Gurevich VV, Chavkin C (2002) mu-Opioid receptors desensitize less rapidly than delta-opioid receptors due to less efficient activation of arrestin. J Biol Chem 277:15729-15735.
30. Lester PA, Traynor JR (2006) Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res 1073-1074:290-296.
31. Peckham EM, Traynor JR (2006) Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 316:1195-1201.
32. Dang VC, Napier IA, Christie MJ (2009) Two distinct mechanisms mediate acute muopioid receptor desensitization in native neurons. J Neurosci 29:3322-3327.
33. Bogoyevitch MA, Kobe B (2006) Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70:1061-1095.
34. Kam AY, Chan AS, Wong YH (2004) Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase. J Neurochem 89:391-402.
35. Jin W, et al. (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-3780.
36. Wu DF, et al. (2008) Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors. J Neurochem 104:1132-1143.
37. Smith C, et al. (2006) Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor. Mol Pharmacol 70:1264-1270.
38. Toohey N, Klein MT, Knight J, Smith C, Teitler M (2009) Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists." Mol Pharmacol 76:552-559.
39. Schuller AG, et al. (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151-156.
40. Clayton CC, Bruchas MR, Lee ML, Chavkin C (2010) Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77:339-347.